U.S. Markets closed

BG Medicine announces preliminary decision by CMS on BGM Galectin-3 test

BG Medicine announced that the Centers for Medicare and Medicaid Services, or CMS, have made a preliminary decision to set the Medicare payment rate for the Company's BGM Galectin-3 test at the amount of a cross walked test whose 2013 national limitation amount is $30.24, subject to a final determination by CMS by year-end 2013. The new payment rate, if finalized, will replace the BGM Galectin-3 test's national limitation amount of $17.80 that was effective in 2013. This preliminary determination by CMS comes in response to BG Medicine's request for reconsideration of the 2013 CMS determination. The BGM Galectin-3 test is a novel test, which is cleared by the FDA as an aid in assessing the prognosis of patients with chronic heart failure.